CINP are please to announce the following companies are confirmed sponsors or exhibitors at the Congress, Vienna 2018
Asian College of Neuropsychopharmacology (AsCNP) was founded in 2008, based on the need to elucidate the mechanisms that underlie the effects of medications for the treatment of central nervous system disorders, develop new medications, and appropriately utilize such medications in Asia. The mission of AsCNP is to encourage research, facilitate the communication of ideas in converging disciplines of neuropsychopharmacology in Asia, develop pharmacotherapies for the treatment for psychiatric disorders, provide education and training opportunities, and empower patients and their families with scientific knowledge. AsCNP currently has more than 3000 members. The 6th AsCNP Congress will be held in Fukuoka, Japan, on October 11-13, 2019.
Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan operating globally in major pharmaceutical markets, including Japan, the United States, China and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area and the Oncology area, which have been designated as the focus therapeutic areas. www.ds-pharma.com
BrainsWay is engaged in the research, development and marketing of BrainsWay Therapy, a non-invasive treatment of brain-disorders. Based on a unique technology, it can reach deeply and broadly into the brain and produce nerve stimulation. The treatment has reimbursement covering 90% of the US population and is FDA cleared for the treatment of MDD, and CE marked for MDD, OCD, Smoking Cessation, PTSD and more
Cambridge Cognition is a neuroscience digital health company developing products and technologies to enhance research of the brain and measure cognitive health and wellbeing in patients worldwide. Our software is the recognised gold standard digital measure of cognitive biomarkers – tracking improvement and decline of brain health in research, drug development and healthcare.
ECNP is Europe’s leading independent forum for the science of CNS treatments.
The ECNP Congress showcases the world’s best disease-oriented brain research, annually attracting between 4,000 and 6,000 neuroscientists, psychiatrists, neurologists and psychologists. ECNP’s wide range of scientific and educational activities, programmes and events make it the largest non-institutional supporter of applied and translational neuroscience research and education in Europe.
With active individual members in as many as 88 countries and 42 National Psychiatric Association (NPA) Members who represent more than 80,000 European psychiatrists, the
European Psychiatric Association is the main association representing psychiatry in Europe. The EPA’s activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. The EPA deals with psychiatry and its related disciplines, and focuses on the improvement of care for the mentally ill as well as on the development of professional excellence.
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, depression, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on http://www.janssen.com/emea/.
Follow us on www.twitter.com/janssenEMEA for our latest news.
Karger Publishers in Basel, Switzerland, is a globally active medical and scientific publishing company. Independent and family-run in the fourth generation by Vice Chairwoman & Publisher Gabriella Karger and Chairman Thomas Karger, the company is dedicated to serving the information needs of the scientific community with publications of high-quality content, covering all fields of medical science. The publication program comprises 50 new books per year and 105 peer-reviewed journals with a growing number of open-access publications. Karger content is published predominantly in English, with a strong focus on basic and clinical research, and is in general available online.
S. Karger AG consists of the publishing company Karger Publishers (est. 1890) and the International Subscription Agency Karger Libri (est. 1960).
Lundbeck – improved treatment and a better life for people living with psychiatric and neurological disorders
A global pharmaceutical company specialised in psychiatric and neurological disorders.
For more than 70 years, we have been at the forefront of research in neuroscience with focus on depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
NAPICU is a rapidly expanding organisation committed to developing and promoting the psychiatric intensive care speciality.
NAPICU aims to improve service user experience, outcome and promote staff support and development with PICUs/LSUs by:
- Improving mechanisms for the delivery of psychiatric intensive and low secure care
- Auditing effectiveness
- Promoting research, education, practice development
The association uses a number of tools and methods to meet these aims, including Quarterly Meetings, website, and the Annual Conference.
NAPICU publish their own Journal: Journal of Psychiatric Intensive Care
One of NAPICU’s strengths lies in the fact that it is a truly multidisciplinary clinician led organisation.
Oxford University Press is the proud publisher of the International Journal of Neuropsychopharmacology (IJNP), the official journal of the CINP. The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. IJNP is fully Open Access, and ranked in the top 25% of Clinical Neurology journals (according to Journal Citation Reports®). OUP publishes some of the world’s leading neuroscience books, journals, and online resources.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites: www.ds-pharma.com, www.sunovion.com, www.sunovion.eu and www.sunovion.ca.
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
15 Lyon Road
Tel +44 (0) 208 715 1812
Join us at the World Congress from the 11th – 15th October in Glasgow, Scotland as the field of Psychiatric Genetics enjoys a period of rapid discovery. Clinical psychiatry is moving toward a future where basic science discoveries are translated in-to genuine improvements in person-centered care. The 2018 WCPG ‘Bench, Brain, and Bedside’ will feature a wide-ranging program of speakers and sessions that will appeal to scientists and clinicians alike, while also engaging with the public.
More information is available on-line: WCPG2018.org
The 14th World Congress of Biological Psychiatry will take place from 2 – 6 June 2019 in Vancouver, Canada.
The theme of the WFSBP Congress 2019 is “Neuroscience Discoveries and Translation to Clinical Practice” and was chosen to address two major challenges plaguing the field of mental health i.e. slow progress in new discoveries and barriers to evidence based application of new discoveries in day to day clinical practice to improve patient care.
The congress will be structured to include a neuroscience discovery track and a clinical track. Within each track, plenaries, round table debates, workshops, symposia and short oral presentation sessions will address cutting edge topics. Priority will be given to symposia and workshop proposals that report on new methods and tools in biological psychiatry and psychopharmacology and their translational aspects.
World Psychiatric Assocation (WPA)